Sharechat Logo

AFT posts loss that meets estimates in maiden result as Australian sales overtake NZ

Wednesday 25th May 2016

Text too small?

AFT Pharmaceuticals, the Auckland-based drug developer, posted a $8.9 million operating loss for the year to March 31, its first result since listing on the NZX and ASX last December, and in line with analyst expectations.

Total revenue rose 14 percent to $64 million, in part reflecting ongoing fast sales growth in the Australian market of its flagship ibuprofen-paracetamol painkiller, Maxigesic. Australian sales rose 19 percent to $31.2 million while New Zealand revenue rose 5.8 percent to $31.1 million.

‚ÄčTotal sales in South East Asia and the rest of the world totalled $1.7 million, but showed exponential growth and the company reported Maxigesic is now licenced for sale in 98 countries, is moving from behind-the-counter to on-the-shelf sales in Australia meaning it can also be advertised, and that first licencing income was booked from Italy, while the product is due for launch in Singapore next month and in Britain and Eastern Europe "soon".

AFT is also undertaking clinical trials of an oral dose Maxigesic product in seven countries, its Maxigesic IV product in New Zealand and the US, and plans to launch clinical studies of its NasoSURF nebuliser for treatment of sinus conditions later this year. The company regards the sinusitis treatment device as a larger opportunity in the long term than Maxigesic, which is driving growth at present.

No financial forecasts were given at the time of last year's listing at an issue price of $2.80, but First NZ Capital initiated coverage of the stock in February, rating it 'outperform' with a target price of $3.25 and predicting an annual adjusted earnings loss of $8.7 million. The company reported a 1 percentage point reduction in average gross margin to 37 percent.

 AFT shares closed yesterday on the NZX at $3.02.

The company raised $35.6 million going public and said it had $28.1 million in cash available at balance date, after spending $8.4 million during the year on research and development - a 46 percent increase.

Listing costs of $2.6 million and much-reduced finance costs of $2 million, down from $7.2 million in the previous year, produced a total loss after tax of $13.3 million, from $12.9 million the previous year.

AFT was expected to make a loss in the current financial year, said founder chief executive Hartley Atkinson, "due to significant investment in accelerating clinical studies for key innovative products."

That programme was scheduled to be "substantially completed" during the current and next financial year, "after which we are targeting a return to positive earnings before tax, interest, depreciation and amortisation."

BusinessDesk.co.nz

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZ dollar falls with Aussie after Westpac's RBA rate cut call
Intuit juggernaut grows QuickBooks subscribers but momentum slows
Reaction to Budget rules relaxation shows balance 'about right', says Ardern
Augusta lifts net profit six fold as investors flock into new funds
Annual exports to China top $15 billion for first time
Gentrack posts $8.7M loss on CA Plus write-down
Westpac says RBNZ capital proposals would add $6,000 p.a. to an Auckland mortgage
Cavalier says market conditions still challenging
Ryman hikes dividend as annual earnings grow on wider development margin
24th May 2019 Morning Report

IRG See IRG research reports